Protein Fv (pFv) is a recently described 175-kD gut-associated sialoprotein with a potent capacity for augmentation of antibody-dependent immune functions. To investigate the molecular basis for Fab-mediated binding of pFv, we evaluated a panel of 52 monoclonal IgM and found that -40% bound pFv. Whereas the majority (2 75% ) of VH3 and VH6
Introduction
Protein Fv (pFv)' is a 175-kD dimeric sialoprotein, produced in the human liver, which has unique properties that may aid in immune defense in the gut. In vitro studies have demonstrated that binding of pFv by antibodies enhances complement activation ( 1) , and by interacting with the Fab domain of the surface membrane-associated IgE, pFv can also aid in the release of histamine and sulfidopeptide leukotriene C4 by human basophils and mast cells (2) . In addition, in vitro studies indicate that the addition of pFv augments agglutination of pathogens by antivirus and by anti-Salmonella typhi antibodies, which may improve conveyance in the mucus stream and excretion of pathogens from the gut (3) .
pFv derives these diverse functional properties from its unique Fab binding activity. A single molecule of pFY can bind six F(ab' )2 fragments (2) . The pFv binding capacities of different antibodies vary greatly, but IgM, IgA, IgG, and IgE can display pFv binding activity (4, 5) . pFv binding capacity has also been detected in the Ig from a variety of mammalian, avian, reptilian, amphibian, and fish species (4) . Studies using isolated Ig fragments have clearly demonstrated that binding to pFv is mediated by the VH region (5) . As this interaction does not block binding of either IgG or IgM antibodies to their conventional ligands, pFv presumably interacts with Fab outside of the conventional antigen-binding pocket (3, 5) .
To investigate the molecular basis for antibody binding of pFv, we applied approaches and insights originally developed for studies of Fab-mediated binding of staphylococcal protein A (SpA) (6) (7) (8) (9) (10) . We sought to evaluate the spectrum of VH regions used in pFv binding and determine whether binding of pFv could preferentially select for antibodies encoded by certain VH gene segments. The pFv binding capacity of a panel of human monoclonal IgM was first evaluated, and we investigated binding within large antibody repertoires of a healthy adult obtained from combinatorial Fab phage-display libraries. These studies revealed that the affinity of pFv binding is comparable to that of a conventional antigen binding interaction, but the frequency of binders and the structural correlates for the interaction are akin to those of a superantigen.
Methods
Immunoblot analysis of IgM binding to pFv. The isolation of pFv has previously been described (11) , and the activity and purity of the pFv preparations from donors TER and FAR have been extensively documented (2) (3) (4) (5) 11) . To identify the IgM proteins that bind pFv, lOXconcentrated pFv samples or control proteins were dissolved in reducing (8 M urea and 2-mercaptoethanol) buffer and electrophoretically separated on 10% polyacrylamide gels, as previously described (10, 12) . Replicate gels were electrotransferred to Immobilon P membrane (Millipore Corp., Bedford, MA), air dried, rewetted, and blocked with 1% nonfat dried milk, 0.1% gelatin in borate-buffered saline, pH 8.2 (BBS) for 1 h. Immunoblots were incubated with IgM preparations at 1 jig/ ml in blocking solution for 1 h at room temperature with rocking, followed by extensive washing with 0.05% Tween 20-BBS and incubation with horseradish peroxidase-conjugated goat anti-human IgM overnight at 40C. Plates were emptied and rinsed once with distilled water and then incubated with pFv from donor TER (2) (3) (4) (5) 11) , or a control antigen, orosomucoid (Novabiochem) at 1 /.sg/ml in water with 0.25% glutaraldehyde for 1 h at 37TC. Wells were emptied and blocked by completely filling with 100 mM glycine, 0.1% BSA in PBS, pH 7.2, for 30 min at room temperature. Plates were further blocked with 3% BSA in 0.1 M NaHCO3, pH 8.6, for 30 min at 370C. Other control antigens, transferrin, actin, BSA, or tetanus toxoid was precoated on wells at 5 ug/ml in PBS overnight at 40C and then blocked with 1% BSA in PBS for 1 h at room temperature. IgM proteins, Fab, or a polyclonal IgM standard at 1 Itg/ml in 1% BSA in 0.1 M NaHCO3, pH 8.6, was then added in replicate, and the plates were sealed and incubated for 90 min at 37TC. Plates were washed five times with 0.05% Tween 20-BBS and incubated with horseradish peroxidase-labeled anti-human IgG Fab (Pierce, Rockford, IL) diluted 1:3,000 in PBS for 1 h at room temperature. Plates were washed five times and developed with substrate. The human monoclonal IgM include antibodies with rheumatoid factor, anti-I/i cold agglutinin, anti-pneumococcal polysaccharide type 3, anti-DNA, and anti-Sm specificity (sources reported in references 6, 8, 13, and 14) . Fab-producing bacterial clones were tested for pFv binding activity only if the plasmids contained the appropriately sized V gene inserts and produced detectable light (L) chains. Designation as an pFv binder required an absorbance greater than twice the mean of negative controls (or greater than five times SD above negative controls) and > 30% inhibition of pFv binding activity by soluble pFv in competition ELISA.
The evaluation of the antibody binding capacity of Fab from the phagemid libraries used previously described methods (9, (15) (16) (17) . The bacterial supernatants were used directly or stored at -20°C. By comparison with human IgG Fab (Novabiochem) standards, the concentration of the Fab in each extract was measured as previously described except plates were precoated with affinity-purified goat anti-human IgG Fab (Sigma Chemical Co., St. Louis, MO) at 5 qg/ml in PBS, pH 7.2, overnight at 4°C and then blocked with 1% BSA in PBS for 1 h at room temperature before addition of the samples in replicate.
To compare binding avidities and determine whether antibodies recognized a common site on pFv, competition ELISA was performed using purified adult polyclonal IgM (Novabiochem) that was labeled with N-hydroxyl-succimide-biotin (Novabiochem). ELISA wells were precoated with pFv, as previously described, and replicate wells were incubated with either polyclonal IgM-biotin at 500 ng/ml alone or polyclonal IgM-biotin at 500 ng/ml with different concentrations of unlabeled antibodies or IgG Fc for 1 h at 37°C. By comparison with a series of dilutions of polyclonal IgM-biotin in the absence of inhibitor, the relative inhibition was determined (e.g., values equivalent to that for polyclonal IgM-biotin at 250 ng/ml represented 50% inhibition).
Surface plasmon resonance determinations ofpFv binding affinity.
Binding kinetics were measured using the surface plasmon resonance technique on the BlAcore instrument (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) (18, 19) . This enables real-time kinetics analysis of antibody-antigen interactions in a label-free mode. Immobilization of the pFv and the binding of all subsequent molecules were measured using a direct optical sensing technique based on total internal reflectance. Adapting the ELISA precoating procedure, activation solution (Pharmacia LKB Biotechnology Inc.) was used to immobilize 0.1% poly-L-lysine (Sigma Chemical Co.) on the 100-nm-thick layer of dextran coating the gold film of the biosensor chip (18) , resulting in a signal increase of 3,400 RU. Next, a 1OX-concentrated pFv (donor TER) solution with 0.25% glutaraldehyde was added, resulting in a signal increase of 4,100 RU. The surface was then blocked by two consecutive injections of 3% BSA plus 0.1 M NaHCO3, pH 8.6, and 1% BSA plus 0.1 M NaHCO3, pH 8.6. To assess binding, each antibody was added at final concentrations of 5-500 jg/ml. PBS was allowed to flow over the surface after each injection for 10 min so that at least 30% of the bound antibody dissociated. The binding was displayed in real time as a sensogram, which was analyzed using kinetics software to give final affinity values (19) .
Creation of combinatorial Ig libraries. Using previously described methods (9, (15) (16) (17) , we recently constructed an IgG library (9), now designated JG. An IgM library, designated JM, was made from the same peripheral blood sample that was the source of the JG library, and this also used the same L chain phagemid library used for the JG library. To amplify the heavy (H) chain genes, in separate reactions an antisense (downstream) primer (termed CM1) (5'-GCTCACACTAGTAGG-CAGCTCAGCAATCAC-3') derived from the 1 constant region was paired individually with sense (upstream) VH oligonucleotide primers from the previously described panel, with an additional VH primer, (5'-CAGGTGCAGCTACTCGAGTGGGGC-3'), designated VH4gs, which ensured representation of rearrangements of the VH4-21 gene segment. The H chain genes were cloned after the L chain genes to avoid destroying VH4-21 rearrangements, which contain internal SacI sites. In these libraries, there were > 107 CFU for both H and L chain transformants. The PCR conditions used are associated with < 1 mutation in 1,500 bases due to Taq polymerase infidelity. Each pComb3 clone was designated according to the library from which it was obtained (JM or JG).
Clones from the original library include the "0" prefix, and selected clones include the prefixes pFv 1-, pFv2-, and pFv3-, based on the round of selection.
Antibody selection. As previously described (9, (15) (16) (17) , antigenspecific clones were selected using a modified panning procedure (20) . For selection of pFv-specific clones, microtiter wells were precoated and blocked as previously described. For each round of selection, two of these wells were filled with 50 1d of phage library containing 1011 CFU in PBS and incubated for 2 h at 370C. After extensive washing, binding phage were eluted with glycine-HCl, pH 2.5, which was rapidly neutralized with 2 M Tris-base. Phage were then amplified.
Colony hybridization to survey VH family diversity. To survey VH chain diversity within the pComb3 clones, an oligonucleotide-based hybridization method was adapted (9, 10, 21) (CR-2), 5 '-GGTCCATGTTGGTCAYl ITlAAGGACCACCTGGTTT- All hybridization studies were performed at least twice to ensure accuracy. On all blots, control VH-containing plasmids were included to document specificity and signal intensity: 51PI (VHl), M60, (VH2), 30P1 (VH3), 58P2 (VH4), 83P2 (VHS), M71 (VH6), and 10PI (VH7).
DNA sequence determination. The nucleotide sequences encoding VH and VL regions were determined from double-stranded DNA using automated sequencing (Applied Biosystems, Inc., Foster City, CA). The oligonucleotide 5'-ATGGAGTCGGGAAGGAAGTC-3', termed SEQMB, from the ti constant region immediately adjacent to the VH region and other previously described oligonucleotides (9) Fig. 3 . Except where indicated, these IgM use VJllI L chains, and usage was presented in earlier publications (6, 8, 13, 14) . For VH4, 0/1 VHS, and 3/4 VH6 IgM, displayed significant ELISA reactivity with pFv. Binding specificity was confirmed by demonstration that soluble pFv inhibited the interaction with solid phase pFv (data not shown). IgM from the VHl and VH4 families with pFv binding activity generally had weaker pFv binding activity than displayed by the VH3 and VH6 IgM binders. Binding to a panel of control antigens was also tested, but the IgM were uniformly nonreactive except for the VH6 IgM, L16, which had significant binding activity with orosomucoid, a control sialoprotein preparation.
Inhibition of polyclonal IgM pFv binding by monoclonal IgM. In competitive binding studies, three VH3 IgM, 18/2, Kim4.6, and Huab2-3, were potent inhibitors. The VH3 IgM Huabl4-3, the VH6 IgM L16, and polyclonal IgM had intermediate inhibition capacity. The VH1 IgM KAS was the weakest inhibitor ( Fig. 2) . At higher concentrations, the five different monoclonal IgM were each able to significantly inhibit (75-97%) pFv binding by polyclonal IgM (Fig. 2) . Of those tested, the best inhibitors were the IgM-K 18/2 and the IgM-X KIM4.6, which use VH3 regions encoded by the germline configuration of the VH26c/V3-23 and 1.9III/V3-30 gene segments, respectively (23) (24) (25) (Fig. 3) , surface plasmon resonance studies indicated that the VH6 IgM L16 interacts with pFv with an apparent association constant (Ka) of 8.8 X 107 M-1, and the four VH3 IgM, Hum2-3, Hum 14-3, 18/2, and KIM4.6, bind with a Ka of 0.11-6.7 x 108 M-1 (Table I) . Consistent with the results of the competitive binding assays, the IgM 18/2 and KIM4.6 displayed the strongest binding interactions with pFv. The VH region of the IgM-K Fab JMSpA3-15 expresses the germline configuration of VH26c/ V3-23, which differs by only 4 amino acids in this portion from the IgG-X Fab JGSpA3-08 (Fig. 3) . These Fab, which are capable of only monovalent interactions, bind pFv with Ka values of 1.9 and 3.5 x 106 M-', respectively. In an earlier report (9) , the unselected JG library was shown to contain 26% VH1, 26% VH3, and 26% VH4 y rearrangements (other VH families were not assessed). A total of 21 IgG Fab Table H ). The JG library was subjected to three rounds of panning with pFv. 12 representative clones from the resultant library were evaluated, and 7 IgG Fab clones had significant pFv binding activity (data not shown).
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V region sequence analyses ofFab with pFv binding capacity. The complete DNA sequences were determined for the VH regions of six IgM Fab clones with pFv binding, activity obtained from the unselected JM library, which included JM 0-131 (VH1 ), JM 0-42 (VH3) JM 0-28X (VH4), JM 0-26X (VH4), JM 0-133 (VH4), and JM 0-8X (VH6). From sequence analysis, all were derived from independent VH rearrangements ( Fig. 3 ; Table III ). Included in Fig. 5 are the VH sequences available for nine intact IgM with pFv binding capacity.
The VH sequences of 15 representatives of the JMpFv2 library obtained after two rounds of selection with pFv were also determined (Fig. 3) . These VH genes appear to derive from only seven different rearrangements. JMpFv2-5 1 (VH3), JMpFv2 
JMpFv2-58/56 (VH6).
A total of six VH region sequences were determined for representative clones from the JG library obtained after three rounds of biopanning with pFv (Fig. 3) . Of these, four, JGpFv3- cal, the associated L chains are encoded by a K gene and a X VH26cIV3-23 (24, 30) 3a 3
VH26cJV3-23 (24, 30) 3a 3
VH26c/V3-23 (24, 30) 3a 3
VH26cIV3-23 (24, 30) hv3019/V3-33 (35) 6a/6f 6 6-IGlIV6-01 (33) 6a/6f 6 6-lGlIV6-01 (33) 6a/6f 6 6-lGlIV6-01 (33) (Table IHI) . Taken together, these data indicate that in mean±SD) and are all smaller than the mean size of VH CDR3 many cases independent antibody clones with identical or highly expressed in the adult repertoire (38, 39 Crystallographic studies have demonstrated that binding pockets for conventional antigens generally occur at the central confluence of the H and L chain CDR loops, and in most cases CDR3 loops, the subdomains of greatest diversity, are highly involved (36, 44, 45) . In contrast, the current variable region analyses did not detect conserved amino acid sequences in any of the CDR of pFv binders, and diverse VH CDR3 were demonstrated to be permissive of pFv binding. However, the library studies did reveal preferential selection for VH CDR3 of a small size. Although the CDR3 could still directly contribute to the pFv-binding site, another plausible explanation is that CDR3 of a particular size are more favorable for the expression of desired conformations of contact sites in another subdomain(s) of the Fab. Alternatively, significantly larger VH CDR3 loops may be selected against because they often protrude from the surface of the classic antigen-binding site (46) and may interfere with access of pFv to another surface of the Fab.
Conserved sequences in the VH framework regions (FRs) correlated best with pFv binding capacity. The FRI and FR3 subdomains create a large solvent-exposed surface separate from the classic antigen-binding pocket, and this surface is highly superimposable on antibodies of the same VH family (44, 45, 47) . Significantly, antibodies encoded by VH26c/V3-23, which were found to have among the strongest pFv binding interactions, contain one of the most highly conserved VH FRI / FR3 surfaces within the human genome (reference 47; G. J. Silverman, manuscript in preparation). This gene also shares high homology with antibody genes from other species with prevalent Fab-mediated binding activity for pFv (4, 47) .
The current study was not designed to discriminate amino acids that correlate with pFv binding from those retained because they help to maintain the overall "immunoglobulin fold" (45) (48) . Mutagenesis studies will be required to address these topics further.
The implications for the production of pFv in the body are little understood, and all of the immune properties of pFv described to date derive from in vitro studies. Though it has not yet been examined, we speculate that after pFv associates with immune complexes within the gut, it may accompany the immune complexes during transepithelial cell transport and influence antigen processing (49, 50) . B lymphocytes that express surface Ig with rheumatoid factor (anti-IgG Fc) activity have been shown to be highly efficient at the capture of small amounts of antigen-associated immune complexes, which results in efficient presentation of a conventional antigen at 1,000-fold lower concentrations than monocytes or macrophages (51) . By analogy, nearly all B lymphocytes should be able to interact via their surface Ig with pFv-associated immune complexes, which should greatly amplify the capacity to internalize and process conventional antigens in an immune complex. This proposed mechanism, in which pFv assists the immune response to ingested antigens, may contribute to the process in which oral immunization of humans results in B cell sensitization and not tolerance (52) .
An influence on repertoire selection should also be considered. In the mouse, there is evidence that during lymphogenesis, certain VH gene segments are used based on their relative position in the Ig locus,-with more JH proximal genes being preferentially rearranged (53) . Although this may explain the preferential use of the human VH6 gene (54) (55) (56) (57) (58) , which is most JH proximal (33, (59) (60) (61) , it certainly does not explain the overexpression of other genes, such as VH26c/V3-23, 1.9111/V3-30, and 4-21NV4-34 (40, 41, 54, 55, 57, (62) (63) (64) , that are scattered throughout the VH locus (61). Auto-antibody-mediated interactions, which include anti-idiotypes, rheumatoid factors, antired cell membrane, anti-DNA, and other specificities, have all been discussed as surrogates for the foreign antigens that later direct B cell repertoire selection (23, 25, (65) (66) (67) . However, the earliest B lymphogenesis occurs in the liver, which suggests that if it is produced during in utero development, pFv could potentially bias clonal selection of the early B cell repertoire. The evidence that V gene segments which are overexpressed in the early repertoire may have preferential binding interactions with pFv makes this hypothesis even more appealing. Preferential binding interactions with B cell receptors with small VH CDR3, a pattern more common during early ontogeny (38, 39) , are also consistent with this speculation. Taken together, the demonstrated high affinity of antibody interactions, potential for multivalent interactions, known localization to the liver, and the broad range of Fab that can bind all favor a role for pFv in receptor-mediated selection of the human B lymphocyte repertoire.
In summary, recent studies have demonstrated that there is a class of proteins for which there are naturally occurring B cell receptor-binding sites that are created predominantly by the contribution of the VH gene segment. The minimal structural requirements for the creation of these sites explain why they are highly prevalent among human lymphocyte populations. Within the current studies, we have investigated the molecular basis for Fab-mediated binding of pFv. This human liver protein has the broadest of known variable region mediated-Fab binding capacities and thus the highest frequency of binding interactions with the antibody repertoire of any protein characterized to date. Within the gut, the compartmentalized and regulated expression of pFv may greatly contribute to B cell/antibodymediated immune defenses. Recent reports suggest that SpA and the gpl2O envelope proteins of certain HIV-1 strains also interact with similar VH sites (6-9, 22, 68-70) . Although yet to be proven, these infectious pathogens may have co-opted a physiologic Fab binding functional capacity, to interfere with opsonization of pathogens and normal B cell regulation within extravascular sites. Further studies will be required to investigate the physiologic expression of pFv and consider the role of pFv in the acquisition of immune competence.
